Randomized trial of carboplatin versus radiotherapy for stage I seminoma: Mature results on relapse and contralateral testis cancer rates in MRC TE19/EORTC 30982 study (ISRCTN27163214)

Journal of Clinical Oncology

Volumn 29, Issue 8, 2011, Pages 957-962

  Oliver, R Timothy D ^a   Mead, Graham M ^a   Rustin, Gordon J S ^a   Joffe, Johnathan K ^a   Aass, Nina ^a   Coleman, Robert ^a   Gabe, Rhian ^a   Pollock, Philipy ^a   Stenning, Sally P ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; EDETIC ACID; FOLLITROPIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER STAGING; CONTROLLED STUDY; CREATININE CLEARANCE; GLOMERULUS FILTRATION RATE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RADIATION DOSE; RADIATION HAZARD; RANDOMIZED CONTROLLED TRIAL; SEMINOMA;

ANTINEOPLASTIC AGENTS; CARBOPLATIN; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; EUROPE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; ORCHIECTOMY; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RADIATION DOSAGE; RADIOTHERAPY, ADJUVANT; RISK ASSESSMENT; RISK FACTORS; SEMINOMA; TESTICULAR NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME;

EID: 79952741548     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.26.4655     Document Type: Article

References (32)

1. Powles T, Bhardwa J, Shamash J, et al: The changing presentation of germ cell tumours of the testis between 1983 and 2002. BJU International 95:1197-1200, 2005
2. Warde P, Specht L, Horwich A, et al: Prognostic factors for relapse in stage I seminoma managed by surveillance: A pooled analysis. J Clin Oncol 20:4448-4452, 2002 (Pubitemid 35334756)
3. Martin JM, Panzarella T, Zwahlen DR, et al: Evidence-based guidelines for following stage 1 seminoma. Cancer 109:2248-2256, 2007 (Pubitemid 46801554)
4. Zagars GK, Ballo MT, Lee AK, et al: Mortality after cure of testicular seminoma. J Clin Oncol 22:640-647, 2004 (Pubitemid 41095067)
5. de Wit R, Fizazi K: Controversies in the management of clinical stage I testis cancer. J Clin Oncol 24:5482-5492, 2006
6. Powles T, Robinson D, Shamash J, et al: The long-term risks of adjuvant carboplatin treatment for stage I seminoma of the testis. Ann Oncol 19:443-447, 2008 (Pubitemid 351336907)
7. Oliver T: Conservative management of testicular germ-cell tumors. Nature Clinical Practice Urology 4:550-560, 2007
8. Fosså SD, Horwich A, Russell JM, et al: Optimal planning target volume for stage I testicular seminoma: A Medical Research Council randomized trial - Medical Research Council Testicular Tumor Working Group. J Clin Oncol 17:1146, 1999
9. Jones WG, Fosså SD, Mead GM, et al: Randomized trial of 30 versus 20 Gy in the adjuvant treatment of stage I testicular seminoma: A report on Medical Research Council Trial TE18, European Organisation for the Research and Treatment of Cancer Trial 30942 (ISRCTN18525328). J Clin Oncol 23:1200-1208, 2005 (Pubitemid 46202277)
10. Oliver RTD, Mason MD, Mead GM, et al: Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage 1 seminoma: A randomised trial. Lancet 366:293-300, 2005 (Pubitemid 41019418)
11. Calvert AH, Egorin MJ: Carboplatin dosing formulae: Gender bias and the use of creatinine-based methodologies. Eur J Cancer 38:11-16, 2002 (Pubitemid 34031819)
12. Warde PR, Chung P, Sturgeon J, et al: Should surveillance should be considered the standard of care in stage I seminoma? J Clin Oncol 23:16S, 2005 (suppl; abstr 4520)
13. Reiter WJ, Kratzik CB, Brodowicz T, et al: Sperm analysis and serum follicle-stimulating hormone levels before and after adjuvant single agent carboplatin therapy for clinical stage I seminoma. Urology 52:117-119, 1998 (Pubitemid 28317940)
14. Mead GM, Fossa S, Oliver R, et al: Relapse patterns in 2466 stage I seminoma patients entered into Medical Research Council (MRC) randomised trials. J Clin Oncol 26:255s, 2008 (suppl; abstr 5020)
15. Wanderas E, Fossa SD, Heilo A, et al: Serum follicle stimulating hormone: Predictor of cancer in the remaining testis in patients with unilateral testicular cancer. Br J Urol 66:315-317, 1990 (Pubitemid 20298510)
16. Harland SJ, Cook PA, Fossa SD, et al: Intratubular germ cell neoplasia of the contralateral testis in testicular cancer: Defining a high risk group. Journal of Urology 160:1353-1357, 1998 (Pubitemid 29480515)
17. Christensen TB, Daugaard G, Geertsen PF, et al: Effect of chemotherapy on carcinoma in situ of the testis. Ann Oncol 9:657-660, 1998 (Pubitemid 28318200)
18. Oliver RTD, Ong J, Berney D, et al: Testis conserving chemotherapy in germ cell cancer: Its potential to increase understanding of the biology and treatment of carcinoma-in-situ. APMIS (Acta Pathologica, Microbiologica et Immunologica Scandinavica) 111:86-92, 2003 (Pubitemid 36569273)
19. Heidenreich A, Weissbach L, Holtl W, et al: Organ sparing surgery for malignant germ cell tumor of the testis. J Urol 166:2161-2165, 2001 (Pubitemid 33065246)
20. Ng R: The reproductive imperative: A case report highlighting the possibility of using chemotherapy to conserve the testis in patients with testis cancer. Clin Oncol 9:334-337, 1997
21. Dieckmann K, Bruggeboes B, Pichlmeier U, et al. Adjuvant treatment of clinical stage 1 seminoma: Is a single course of carboplatin sufficient? Urology 55:102-106, 2000
22. Oliver T, Powles T, Somasundram U, et al: 22 year phase 1/2 study of single agent carboplatin in metastatic seminoma:could it have been accelerated by 72 hour PET scan response? J Clin Oncol 24:642s, 2006 (suppl; abstr 14565)
23. Bokemeyer C, Kollmannsberger C, Stenning SP, et al: Metastatic seminoma treated with either single agent carboplatin or cisplatin-based combination chemotherapy: A pooled analysis of two randomised trials. Br J Cancer 91:683-687, 2004 (Pubitemid 39141624)
24. Krege S, Boergermann C, Baschek R, et al: Single agent carboplatin for CS IIA/B testicular seminoma: A phase II study of the German Testicular Cancer Study Group (GTCSG). Ann Oncol 17:276-280, 2006 (Pubitemid 43160118)
25. Aparicio J, Garcia del Muro X, Maroto P, et al: Multicentre study evaluating a dual policy of postorchiectomy surveillance and selective adjuvant single-agent carboplatin for patients with clinical stage I seminoma. Ann Oncol 14:867-872, 2003 (Pubitemid 36827202)
26. Aparicio J, Germa JR, Garcia del Muro X, et al: Risk-adapted management for patients with clinical stage I seminoma: The Second Spanish Germ Cell Cancer Cooperative Group study. J Clin Oncol 23:8717-8723, 2005 (Pubitemid 46211516)
27. Oliver T, Dieckmann K-P, Steiner H, et al: Pooled analysis of phase II reports of 2 versus 1 course of carboplatin as adjuvant for stage 1 seminoma. J Clin Oncol 23:395s, 2005 (suppl; abstr 4572)
28. Huddart RA, Joffe JK: Preferred treatment for stage I seminoma: A survey of Canadian radiation oncologists. Clin Oncol (R Coll Radiol) 18:693-695, 2006 (Pubitemid 44464052)
29. Hoffman KE, Chen MH, Punglia RS, et al: Influence of year of diagnosis, patient age, and sociodemographic status on recommending adjuvant radiation treatment for stage I testicular seminoma. J Clin Oncol 26:3937-3942, 2008
30. Krege S, Beyer J, Souchon R, et al: EGCCCC European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer: A report of the Second Meeting of the European Germ Cell Cancer Consensus group (EGCCCG) - Part I. Eur Urol 53:478-496, 2008
31. Sodickson A, Baeyens PF, Andriole KP, et al: Recurrent CT, cumulative radiation exposure, and associated radiation-induced cancer risks from CT of adults. Radiology 251:175-184, 2009
32. Medical Research Council Clinical Trials Unit: MRC CTU trial protocol: TE24/TRISST (Trial of Imaging and Surveillance in Seminoma Testis). London, United Kingdom, Medical Research Council Clinical Trials Unit, 2008